| No. |
Proposition |
|
For |
Against |
Abstain |
| 1 |
Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2024. |
|
|
|
|
| 2 |
Approval of the appropriation of financial results. |
|
|
|
|
| 3 |
Discharge of the members of the Board of Directors and the Executive Committee. |
|
|
|
|
| 4 |
Re-election of Samarth Kulkarni, Ph.D., as member and Chairman |
|
|
|
|
| 5 |
Re-election of Ali Behbahani, M.D. |
|
|
|
|
| 6 |
Re-election of Maria Fardis, Ph.D. |
|
|
|
|
| 7 |
Re-election of H. Edward Fleming, Jr., M.D. |
|
|
|
|
| 8 |
Re-election of Simeon J. George, M.D. |
|
|
|
|
| 9 |
Re-election of John T. Greene |
|
|
|
|
| 10 |
Re-election of Katherine A. High, M.D. |
|
|
|
|
| 11 |
Re-election of Sandesh Mahatme, LL.M. |
|
|
|
|
| 12 |
Re-election of Christian Rommel, Ph.D. |
|
|
|
|
| 13 |
Re-election of Douglas A. Treco, Ph.D. |
|
|
|
|
| 14 |
Election of Briggs W. Morrison, M.D. |
|
|
|
|
| 15 |
Re-election of the member of the Compensation Committee: Ali Behbahani, M.D. |
|
|
|
|
| 16 |
Re-election of the member of the Compensation Committee: H. Edward Fleming, Jr., M.D. |
|
|
|
|
| 17 |
Re-election of the member of the Compensation Committee: John T. Greene |
|
|
|
|
| 18 |
Election of the member of the Compensation Committee: Briggs W. Morrison, M.D. |
|
|
|
|
| 19 |
Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders. |
|
|
|
|
| 20 |
Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders. |
|
|
|
|
| 21 |
Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2025 to June 30, 2026. |
|
|
|
|
| 22 |
Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2025. |
|
|
|
|
| 23 |
Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders. |
|
|
|
|
| 24 |
Non-binding advisory vote on the 2024 Compensation Report. |
|
|
|
|
| 25 |
Non-binding advisory vote on the compensation paid to the Companys named executive officers under U.S. securities law requirements. |
|
|
|
|
| 26 |
Approval of increasing the maximum size of the Board of Directors. |
|
|
|
|
| 27 |
Re-election of the independent voting rights representative. |
|
|
|
|
| 28 |
Re-election of the auditors. |
|
|
|
|
| 29 |
Transact any other business that may properly come before the 2025 Annual General Meeting or any adjournment or postponement thereof. |
|
|
|
|